Muscular Dystrophy, Duchenne

<section class="Section" data-sectioncode="34089-3"><a name="s23"></a><a name="section-8"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">VILTEPSO (viltolarsen) injection is a sterile, preservative-free, aqueous solution for intravenous administration. VILTEPSO is a clear and colorless solution. VILTEPSO is supplied in single-dose vials containing 250 mg/5 mL viltolarsen (50 mg/mL) in 0.9% sodium chloride. Each milliliter of VILTEPSO contains 50 mg viltolarsen and 9 mg sodium chloride in water for injection. The final product is adjusted to a pH ranging between 7.0 and 7.5 using hydrochloric acid and/or sodium hydroxide.</p><p>Viltolarsen is an antisense oligonucleotide of the phosphorodiamidate morpholino oligomer (PMO) subclass. PMOs are synthetic molecules in which the five-membered ribofuranosyl rings found in natural DNA and RNA are replaced by a six-membered morpholino ring. Each morpholino ring is linked through an uncharged phosphorodiamidate moiety rather than the negatively charged phosphate linkage that is present in natural DNA and RNA. Each phosphorodiamidate morpholino subunit contains one of the heterocyclic bases found in DNA (adenine, cytosine, guanine, or thymine). Viltolarsen contains 21 linked subunits. The molecular formula of viltolarsen is C<span class="Sub">244</span>H<span class="Sub">381</span>N<span class="Sub">113</span>O<span class="Sub">88</span>P<span class="Sub">20</span> and the molecular weight is 6924.82 daltons. The structure and base sequence of viltolarsen are shown in <a href="#fig1">Figure 1</a>.</p><p><a name="fig1"></a><span class="Bold">Figure 1: Structural Formula of Viltolarsen</span></p><div class="Figure"><a name="f01"></a><img alt="Figure
" src="vil01-0004-01.jpg"/></div></section>

Viltepso

viltolarsen

5 ML viltolarsen 50 MG/ML Injection

5 ML viltolarsen 50 MG/ML Injection [Viltepso]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event

Prescribing Information 

Pharmacy List 

How To Order Viltepso

Billing & Coding Guide 

Coverage Authorization Request 

Coverage Authorization Appeals 

NS Support Patient Start Form 

Patient Authorization Form: To be used with NS Start Form 

Enroll in Patient Savings Program 

Patient Assistance Program Application 

Other HCP Resources 

About Viltepso 

Patient Resources 

Viltepso Start Guide 

Patient Brochure 

Infusion Overview Brochure

Instructions For Use: Duchenne Muscular Dystrophy (DMD)